

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

August 2021

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font. Below it, the Māori name "TE PĀTAKA WHAIORANGA" is written in a smaller, uppercase, sans-serif font. The logo is centered within a white circle that overlaps a background of stylized, concentric, wavy lines in shades of gray and white.

Contents

Summary of decisions effective 1 August 2021	3
Section H changes to Part II	8
Index	16

Summary of decisions

EFFECTIVE 1 AUGUST 2021

- Aciclovir (Aciclovir-Baxter) inj 250 mg vial – price increase and addition of PSS
- Atenolol (Mylan Atenolol) tab 50 mg and 100 mg – price increase and addition of PSS
- Atropine sulphate (Martindale) inj 600 mcg per ml, 1 ml ampoule – price increase and addition of PSS
- Azithromycin (Apo-Azithromycin) tab 250 mg – to be delisted 1 May 2022
- Betamethasone valerate (Beta Cream) crm 0.1%, 50 g – price increase and addition of PSS
- Betamethasone valerate (Beta Ointment) oint 0.1%, 50 g – price increase and addition of PSS
- Betamethasone valerate (Beta Scalp) scalp app 0.1%, 100 ml – price increase and addition of PSS
- Brimonidine tartrate (Arrow-Brimonidine) eye drops 0.2%, 5 ml – price decrease and addition of PSS
- Cefepime (Cefepime Kabi) inj 1 g and 2 g vial – new listing and addition of PSS
- Cefepime (Cefepime-AFT) inj 1 g and 2 g vial – to be delisted 1 January 2022
- Cetirizine hydrochloride (Histaclear) oral liq 1mg per ml, 200 ml – price decrease and addition of PSS
- Clonidine hydrochloride (Catapres) tab 150 mg – price increase and addition of PSS
- Clonidine hydrochloride (Medsurge) inj 150 mg per ml, 1 ml ampoule – price increase and addition of PSS
- Cyclophosphamide (Cyclonex) tab 50 mg – new listing and addition of PSS
- Cyclophosphamide (Endoxan and Procytox) tab 50 mg – to be delisted 1 January 2022
- Cyproterone (Siterone) tab 50 mg and 100 mg – price increase and addition of PSS
- Dexamfetamine sulfate (PSM) tab 5 mg – price increase and addition of PSS
- Dexamethasone (Dexmethsone) tab 0.5 mg and 4 mg – price increase and addition of PSS
- Diclofenac sodium (Diclofenac Sandoz) tab EC 25 mg and 50 mg – price increase and addition of PSS
- Diclofenac sodium (Apo-Diclo SR) tab long-acting 100 mg – to be delisted 1 May 2022

Summary of decisions – effective 1 August 2021 (continued)

- Dopamine hydrochloride (Max Health Ltd) inj 40 mg per ml, 5 ml ampoule – price increase and addition of PSS
 - Doxorubicin hydrochloride (Doxorubicin Ebewe) inj 2 mg per ml, 100 ml vial – price increase and addition of PSS
 - Enteral feed 2 kcal/ml (Ensure Two Cal HN RTH) liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle, 1,000 ml – new listing
 - Enteral feed 2 kcal/ml (Two Cal HN RTH) liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle, 200 ml – to be delisted 1 February 2022
 - Epirubicin hydrochloride (Epirubicin Ebewe) inj 2 mg per ml, 100 ml vial – price increase and addition of PSS
 - Febuxostat (Febuxostat multichem) tab 80 mg and 120 mg – new listing and addition of HSS
 - Febuxostat (Adenuric) tab 80 mg and 120 mg – to be delisted 1 January 2022
 - Felodipine (Felo 5 ER) tab long-acting 5 mg – price increase and addition of PSS
 - Felodipine (Felo 10 ER) tab long-acting 10 mg – addition of PSS
 - Fentanyl (Fentanyl Sandoz) patch 12.5 mcg per hour, 25 mcg per hour, 50 mcg per hour, 75 mcg per hour and 100 mcg per hour – price increase and addition of PSS
 - Flucloxacillin (AFT) grans for oral liq 25 mg per ml, 100 ml – price increase and addition of PSS
 - Flucloxacillin (AFT) grans for oral liq 50 mg per ml, 100 ml – addition of PSS
 - Glibenclamide (Daonil) tab 5 mg – price increase and addition of PSS
 - Glucose [dextrose] (HypoPak Glucose) oral soln 15 g per 80 ml sachet – new listing and addition of HSS
 - Hydrocortisone with natamycin and neomycin (Pimafucort) crm 1% with natamycin 1% and neomycin sulphate 0.5%, 15 g – to be delisted 1 May 2022
 - Ibuprofen (Brufen SR) tab long-acting 800 mg – new listing and addition of PSS
 - Ibuprofen (Ibuprofen SR BNM) tab long-acting 800 mg – to be delisted 1 January 2022
 - Isoniazid (PSM) tab 100 mg – price increase and addition of PSS
 - Isoniazid with rifampicin (Rifanah) tab 100 mg with rifampicin 150 mg – price increase
 - Isoniazid with rifampicin (Rifanah) tab 150 mg with rifampicin 300 mg – price increase and addition of PSS
-

Summary of decisions – effective 1 August 2021 (continued)

- Letrozole (Letrole) tab 2.5 mg – price increase and addition of PSS
- Low-GI oral feed 1 kcal/ml (Sustagen Diabetic (Vanilla)) liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per 100 ml, can, 237 ml – delisting delayed from 1 October 2021 to 1 February 2022
- Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride (Glycoprep-C) powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet – new listing and addition of PSS
- Magnesium hydroxide suspension 8% – relocating listing and presentation description change
- Mebendazole (Vermox) tab 100 mg – addition of PSS
- Megestrol acetate (Apo-Megestrol) tab 160 mg – addition of restriction
- Meningococcal (A, C, Y and W-135) conjugate vaccine (Menactra) inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial – amended restriction
- Meningococcal C conjugate vaccine (Neisvac-C) inj 10 mcg in 0.5 ml syringe – amended restriction
- Meningococcal B multicomponent vaccine (Bexsero) inj 175 mcg per 0.5 ml prefilled syringe – amended restriction
- Methadone hydrochloride (Biodone) oral liq 2 mg per ml – price increase and addition of PSS
- Methadone hydrochloride (Biodone Forte) oral liq 5 mg per ml – price increase and addition of PSS
- Methadone hydrochloride (Biodone Extra Forte) oral liq 10 mg per ml – price increase and addition of PSS
- Methotrexate (Trexate) tab 2.5 mg and 10 mg – price increase and addition of PSS
- Midazolam (Mylan Midazolam) inj 1 mg per ml, 5 ml ampoule and 5 mg per ml, 3 ml ampoule – price increase and addition of PSS
- Mirtazapine (Noumed) tab 30 mg and 45 mg – new listing and addition of HSS
- Mirtazapine (Apo-Mirtazapine) tab 30 mg and 45 mg – to be delisted 1 January 2022
- Moclobemide (Aurorix) tab 150 mg and 300 mg – price increase and addition of PSS
- Naproxen (Noflam 250) tab 250 mg – addition of PSS
- Naproxen (Noflam 500) tab 500 mg – price increase and addition of PSS

Summary of decisions – effective 1 August 2021 (continued)

- Naproxen tab long-acting 750 mg (Naprosyn SR 750) and tab long-acting 1 g (Naprosyn SR 1000) – price increase and addition of PSS
 - Nevirapine (Nevirapine Alphapharm) tab 200 mg – price increase and addition of PSS
 - Nifedipine (Mylan 24 hr release) tab long-acting 30 mg and 60 mg – brand name change
 - Orphenadrine citrate (Norflex) tab 100 mg – price increase and addition of PSS
 - Oxytocin with ergometrine maleate (Syntometrine) inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – price increase and addition of PSS
 - Paracetamol (Pacimol) tab 500 mg - blister pack – new listing, presentation description change and addition of HSS
 - Pamidronate disodium (Pamisol) inj 9 mg per ml, 10 ml vial – price increase
 - Paraffin (e.g. QV Bath Oil) lotn liquid paraffin 85% – new listing
 - Perindopril (Apo-Perindopril) tab 2 mg and 4 mg – to be delisted 1 October 2021
 - Pethidine hydrochloride (PSM) tab 50 mg – price increase and addition of PSS
 - Phenoxymethylpenicillin [penicillin V] (Cilicaine VK) cap 250 mg and 500 mg – price increase and addition of PSS
 - Pindolol (Apo-Pindolol) tab 5 mg, 10 mg and 15 mg – addition of restriction and to be delisted from 1 May 2022
 - Pioglitazone (Vexazone) tab 15 mg, 30 mg and 45 mg – price increase and addition of PSS
 - Pirfenidone (Esbriet) tab 267 mg, 90 tab pack – new listing
 - Pirfenidone (Esbriet) cap 267 mg, 270 cap pack – to be delisted 1 January 2022
 - Prazosin (Apo-Prazosin) tab 1 mg, 2 mg and 5 mg – addition of restriction and to be delisted 1 May 2022
 - Rasagiline (Azilect) tab 1 mg – new listing and addition of PSS
 - Rituximab (Riximyo) inj 10 mg per ml, 10 ml and 50 ml vial – amended restriction
 - Salbutamol (Asthalin) nebuliser soln 1 mg per ml, 2.5 ml ampoule and 2 mg per ml, 2.5 ml ampoule – price increase and addition of PSS
 - Salbutamol with ipratropium bromide (Duolin) nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – price increase and addition of PSS
 - Selegiline hydrochloride tab 5 mg – addition of restriction
-

Summary of decisions – effective 1 August 2021 (continued)

- Sildenafil (Vedafil) tab 25 mg, 50 mg and 100 mg – price increase and addition of PSS
- Sodium citrate (Biomed) oral liq 8.8% (300 mmol/l), 90 ml – new listing and addition of PSS
- Sodium hyaluronate [hyaluronic acid] (Hylo-Fresh) eye drops 1 mg per ml, 10 ml – new Pharmacode 2608162 listed and addition of PSS
- Sodium hyaluronate [hyaluronic acid] (Hylo-Fresh) eye drops 1 mg per ml, 10 ml – Pharmacode 2396238 – price decrease and to be delisted 1 January 2022
- Somatropin (Omnitrope) inj 5 mg and 15 mg cartridge – price increase and addition of PSS
- Somatropin (Omnitrope) inj 10 mg cartridge – addition of PSS
- Tobramycin (Tobramycin Mylan) inj 40 mg per ml, 2 ml vial – price increase and addition of PSS
- Tretinoin (ReTrieve) crm 0.05% – price increase and addition of PSS
- Trimethoprim (TMP) tab 300 mg – price increase and addition of PSS
- Trimethoprim with sulphamethoxazole [co-trimoxazole] (Trisul) tab 80 mg with sulphamethoxazole 400 mg – new listing and addition of PSS
- Valaciclovir (Vaclovir) tab 500 mg and 1,000 mg – price increase and addition of PSS
- Varenicline (Varenicline Pfizer) tab 0.5 mg x 11 and 1mg x 42, and tab 1 mg – price decrease and addition of PSS

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 August 2021

ALIMENTARY TRACT AND METABOLISM

5	SODIUM CITRATE (new listing and addition of PSS) Oral liq 8.8% (300 mmol/l) – 5% DV Jan-22 to 2024	25.00	90 ml	Biomed
9	GLUCOSE [DEXTROSE] (new listing and addition of HSS) Oral soln 15 g per 80 ml sachet – 1% DV Jan-22 to 2023	70.00	50	HypoPak Glucose
10	GLIBENCLAMIDE (↑ price and addition of PSS) Tab 5 mg – 5% DV Jan-22 to 2024	7.50	100	Daonil
11	PIOGLITAZONE (↑ price and addition of PSS) Tab 15 mg – 5% DV Jan-22 to 2024	6.80	90	Vexazone
	Tab 30 mg – 5% DV Jan-22 to 2024	7.30	90	Vexazone
	Tab 45 mg – 5% DV Jan-22 to 2024	12.25	90	Vexazone
13	MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE (new listing and addition of PSS) Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet – 5% DV Jan-22 to 2024	218.88	48	Glycoprep-C
19	MAGNESIUM HYDROXIDE (relocating listing and presentation name change) Suspension 8% Note – Magnesium hydroxide suspension has been moved from Extemporaneously Compounded Preparations.			

CARDIOVASCULAR SYSTEM

40	PERINDOPRIL (delisting) Tab 2 mg.....	3.75	30	Apo-Perindopril
	Tab 4 mg.....	4.80	30	Apo-Perindopril
	Note – Apo-Perindopril tab 2 mg and 4 mg brand to be delisted 1 October 2021.			
42	PRAZOSIN – Restricted: For continuation only (addition of restriction and delisting) Tab 1 mg.....	5.53	100	Apo-Prazosin
	Tab 2 mg.....	7.00	100	Apo-Prazosin
	Tab 5 mg.....	11.70	100	Apo-Prazosin
	Note – Apo-Prazosin tab 1 mg, 2mg and 5 mg are to be delisted 1 May 2022.			
42	ATROPINE SULPHATE (↑ price and addition of PSS) Inj 600 mcg per ml, 1 ml ampoule – 5% DV Jan-22 to 2024 ...	15.09	10	Martindale
43	ATENOLOL (↑ price and addition of PSS) Tab 50 mg – 5% DV Jan-22 to 2024	9.33	500	Mylan Atenolol
	Tab 100 mg – 5% DV Jan-22 to 2024	14.20	500	Mylan Atenolol

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	----------------------------------------	-------------------------------------

Changes to Section H Part II – effective 1 August 2021 (continued)

44	PINDOLOL – Restricted: For continuation only (addition of restriction and delisting)		
	Tab 5 mg.....	13.22 100	Apo-Pindolol
	Tab 10 mg.....	23.12 100	Apo-Pindolol
	Tab 15 mg.....	33.31 100	Apo-Pindolol
	Note – Apo-Pindolol tab 5 mg, 10 mg and 15 mg are to be delisted 1 May 2022.		
44	FELODIPINE (addition of PSS)		
	Tab long-acting 5 mg – 5% DV Jan-22 to 2024 (↑ price)	4.07 90	Felo 5 ER
	Tab long-acting 10 mg – 5% DV Jan-22 to 2024	4.32 90	Felo 10 ER
45	NIFEDIPINE (brand name change)		
	Tab long-acting 30 mg.....	34.10 100	Mylan (24 hr release)
	Tab long-acting 60 mg.....	52.81 100	Mylan (24 hr release)
46	CLONIDINE HYDROCHLORIDE (↑ price and addition of PSS)		
	Tab 150 mcg – 5% DV Jan-22 to 2024	37.07 100	Catapres
	Inj 150 mcg per ml, 1 ml ampoule – 5% DV Jan-22 to 2024 ..	29.68 10	Medsurge
49	DOPAMINE HYDROCHLORIDE (↑ price and addition of PSS)		
	Inj 40 mg per ml, 5 ml ampoule – 5% DV Jan-22 to 2024	38.65 10	Max Health Ltd
52	SILDENAFIL (↑ price and addition of PSS)		
	→ Tab 25 mg – 5% DV Jan-22 to 2024	0.85 4	Vedafil
	→ Tab 50 mg – 5% DV Jan-22 to 2024	1.70 4	Vedafil
	→ Tab 100 mg – 5% DV Jan-22 to 2024	10.20 12	Vedafil

DERMATOLOGICALS

55	TRETINOIN (↑ price and addition of PSS)		
	Crm 0.05% – 5% DV Jan-22 to 2024	15.57 50 g	ReTrieve
56	PARAFFIN (new listing)		
	Lotn liquid paraffin 85%		<i>e.g QV Bath Oil</i>
57	BETAMETHASONE VALERATE (↑ price and addition of PSS)		
	Crm 0.1% – 5% DV Jan-22 to 2024	4.53 50 g	Beta Cream
	Oint 0.1% – 5% DV Jan-22 to 2024	5.84 50 g	Beta Ointment
58	HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN (delisting)		
	Crm 1% with natamycin 1% and neomycin sulphate 0.5%	3.35 15 g	Pimafucort
	Note – Pimafucort crm 1% with natamycin 1% and neomycin sulphate 0.5% to be delisted 1 May 2022.		
59	BETAMETHASONE VALERATE (↑ price and addition of PSS)		
	Scalp app 0.1% – 5% DV Jan-22 to 2024	9.84 100 ml	Beta Scalp

GENITO-URINARY SYSTEM

61	OXYTOCIN WITH ERGOMETRINE MALEATE (↑ price and addition of PSS)		
	Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 5% DV Jan-22 to 2024	30.00 5	Syntometrine

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2021 (continued)

HORMONE PREPARATIONS

64	CYPROTERONE ACETATE (↑ price and addition of PSS)			
	Tab 50 mg – 5% DV Jan-22 to 2024	14.37	50	Siterone
	Tab 100 mg – 5% DV Jan-22 to 2024	28.03	50	Siterone
65	DEXAMETHASONE (↑ price and addition of PSS)			
	Tab 0.5 mg – 5% DV Jan-22 to 2024	1.50	30	Dexamethosone
	Tab 4 mg – 5% DV Jan-22 to 2024	2.65	30	Dexamethosone
68	SOMATROPIN (addition of PSS)			
	→ Inj 5 mg cartridge – 5% DV Jan-22 to 2024 (↑ price)	69.75	1	Omnitrope
	→ Inj 10 mg cartridge – 5% DV Jan-22 to 2024	69.75	1	Omnitrope
	→ Inj 15 mg cartridge – 5% DV Jan-22 to 2024 (↑ price)	139.50	1	Omnitrope

INFECTIONS

74	TOBRAMYCIN (↑ price and addition of PSS)			
	→ Inj 40 mg per ml, 2 ml vial – 5% DV Jan-22 to 2024	18.50	5	Tobramycin Mylan
75	CEFEPIME (brand change and addition of PSS)			
	→ Inj 1 g vial – 5% DV Jan-22 to 2024	35.00	10	Cefepime Kabi
	→ Inj 2 g vial – 5% DV Jan-22 to 2024	55.00	10	Cefepime Kabi
	Note – Cefepime-AFT inj 1 g and 2 g vial to be delisted 1 January 2022.			
76	AZITHROMYCIN (delisting)			
	→ Tab 250 mg	8.19	30	Apo-Azithromycin
	Note – Apo-Azithromycin tab 250 mg to be delisted 1 May 2022.			
78	PHENOXYMETHYLPENICILLIN [PENICILLIN V] (↑ price and addition of PSS)			
	Cap 250 mg – 5% DV Jan-22 to 2024	3.84	50	Cilicaine VK
	Cap 500 mg – 5% DV Jan-22 to 2024	6.86	50	Cilicaine VK
78	FLUCLOXACILLIN (addition of PSS)			
	Grans for oral liq 25 mg per ml			
	– 5% DV Jan-22 to 2024 (↑ price)	3.29	100 ml	AFT
	Grans for oral liq 50 mg per ml			
	– 5% DV Jan-22 to 2024	3.68	100 ml	AFT
81	TRIMETHOPRIM (↑ price and addition of PSS)			
	Tab 300 mg – 5% DV Jan-22 to 2024	18.55	50	TMP
81	TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE] (new listing and addition of PSS)			
	Tab 80 mg with sulphamethoxazole 400 mg			
	– 5% DV Jan-22 to 2024	64.80	500	Trisul
84	ISONIAZID (↑ price and addition of PSS)			
	→ Tab 100 mg – 5% DV Jan-22 to 2024	23.00	100	PSM

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 August 2021 (continued)			
85	ISONIAZID WITH RIFAMPICIN (↑ price) → Tab 100 mg with rifampicin 150 mg.....	89.82	100 Rifinah
	→ Tab 150 mg with rifampicin 300 mg – 5% DV Jan-22 to 2024 (addition of PSS)	179.13	100 Rifinah
85	MEBENDAZOLE (addition of PSS) Tab 100 mg – 5% DV Jan-22 to 2024	7.97	6 Vermox
87	NEVIRAPINE (↑ price and addition of PSS) → Tab 200 mg – 5% DV Jan-22 to 2024	84.00	60 Nevirapine Alphapharm
90	ACICLOVIR (↑ price and addition of PSS) Inj 250 mg vial – 5% DV Jan-22 to 2024	10.00	5 Aciclovir-Baxter
91	VALACICLOVIR (↑ price and addition of PSS) Tab 500 mg – 5% DV Jan-22 to 2024	6.50	30 Vaclovir
	Tab 1,000 mg – 5% DV Jan-22 to 2024	13.76	30 Vaclovir

MUSCULOSKELETAL SYSTEM

98	PAMIDRONATE DISODIUM (↑ price) Inj 9 mg per ml, 10 ml vial	75.95	1 Pamisol
102	FEBUXOSTAT (brand change and addition of HSS) → Tab 80 mg – 1% DV Jan-22 to 2023	20.00	28 Febuxostat multichem
	→ Tab 120 mg – 1% DV Jan-22 to 2023	20.00	28 Febuxostat multichem
	Note – Adenuric tab 80 mg and 120 mg to be delisted 1 January 2022.		
103	ORPHENADRINE CITRATE (↑ price and addition of PSS) Tab 100 mg – 5% DV Jan-22 to 2024	20.76	100 Norflex
104	DICLOFENAC SODIUM Tab EC 25 mg – 5% DV Jan-22 to 2024 (↑ price and addition of PSS)	1.99	50 Diclofenac Sandoz
	Tab EC 50 mg – 5% DV Jan-22 to 2024 (↑ price and addition of PSS)	1.99	50 Diclofenac Sandoz
	Tab long-acting 100 mg (delisting)	25.15	500 Apo-Diclo SR
	Note – Apo-Diclo SR tab long-acting 100 mg to be delisted 1 May 2022.		
104	IBUPROFEN (brand change and addition of PSS) Tab long-acting 800 mg – 5% DV Jan-22 to 2024	3.05	30 Brufen SR
	Note – Ibuprofen SR BNM to be delisted 1 January 2022.		
104	NAPROXEN (addition of PSS) Tab 250 mg – 5% DV Jan-22 to 2024	32.69	500 Noflam 250
	Tab 500 mg – 5% DV Jan-22 to 2024 (↑ price)	28.71	250 Noflam 500
	Tab long-acting 750 mg – 5% DV Jan-22 to 2024 (↑ price)	6.47	28 Naprosyn SR 750
	Tab long-acting 1 g – 5% DV Jan-22 to 2024 (↑ price)	8.62	28 Naprosyn SR 1000

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2021 (continued)

NERVOUS SYSTEM

106	RASAGILINE (new listing and addition of HSS) Tab 1 mg – 1% DV Jan-22 to 2024.....	53.50	30	Azilect
107	SELEGILINE HYDROCHLORIDE – Restricted: For continuation only (addition of restriction) Tab 5 mg			
111	PARACETAMOL (new listing, presentation name change and addition of HSS) Tab 500 mg - blister pack – 1% DV Feb-22 to 2024	19.75	1000	Pacimol
112	FENTANYL (↑ price and addition of PSS) Patch 12.5 mcg per hour – 5% DV Jan-22 to 2024..... Patch 25 mcg per hour – 5% DV Jan-22 to 2024..... Patch 50 mcg per hour – 5% DV Jan-22 to 2024..... Patch 75 mcg per hour – 5% DV Jan-22 to 2024..... Patch 100 mcg per hour – 5% DV Jan-22 to 2024.....	6.99 7.99 9.49 17.99 18.59	5 5 5 5 5	Fentanyl Sandoz Fentanyl Sandoz Fentanyl Sandoz Fentanyl Sandoz Fentanyl Sandoz
112	METHADONE HYDROCHLORIDE (↑ price and addition of PSS) Oral liq 2 mg per ml – 5% DV Jan-22 to 2024..... Oral liq 5 mg per ml – 5% DV Jan-22 to 2024..... Oral liq 10 mg per ml – 5% DV Jan-22 to 2024.....	6.40 6.40 7.50	200 ml 200 ml 200 ml	Biodone Biodone Forte Biodone Extra Forte
113	PETHIDINE HYDROCHLORIDE (↑ price and addition of PSS) Tab 50 mg – 5% DV Jan-22 to 2024	4.70	10	PSM
114	MOCLOBEMIDE (↑ price and addition of PSS) Tab 150 mg – 5% DV Jan-22 to 2024	11.80	60	Aurorix
	Tab 300 mg – 5% DV Jan-22 to 2024	19.25	60	Aurorix
114	MIRTAZAPINE (brand change and addition of HSS) Tab 30 mg – 1% DV Jan-22 to 2024	2.60	28	Noumed
	Tab 45 mg – 1% DV Jan-22 to 2024	3.45	28	Noumed
	Note – Apo-Mirtazapine tab 30 mg and 45 mg to be delisted 1 January 2022			
125	MIDAZOLAM (↑ price and addition of PSS) Inj 1 mg per ml, 5 ml ampoule – 5% DV Jan-22 to 2024..... Inj 5 mg per ml, 3 ml ampoule – 5% DV Jan-22 to 2024.....	3.95 3.52	10 5	Mylan Midazolam Mylan Midazolam
127	DEXAMFETAMINE SULFATE (↑ price and addition of PSS) → Tab 5 mg – 5% DV Jan-22 to 2024	21.00	100	PSM
129	VARENICLINE (↓ price and addition of PSS) → Tab 0.5 mg × 11 and 1 mg × 42 – 5% DV Jan-22 to 2024 ... → Tab 1 mg – 5% DV Jan-22 to 2024	16.67 17.62	53 56	Varenicline Pfizer Varenicline Pfizer

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

132	CYCLOPHOSPHAMIDE (brand change and addition of PSS) Tab 50 mg – 5% DV Jan-22 to 2024	145.00	50	Cyclonex
	Note – Endoxan and Procytox tab 50 mg to be delisted from 1 January 2022.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	----------------------------------------	-------------------------------------

Changes to Section H Part II – effective 1 August 2021 (continued)

133	DOXORUBICIN HYDROCHLORIDE (↑ price and addition of PSS) Inj 2 mg per ml, 100 ml vial – 5% DV Jan-22 to 2024	69.99	1	Doxorubicin Ebewe
133	EPIRUBICIN HYDROCHLORIDE (↑ price and addition of PSS) Inj 2 mg per ml, 100 ml vial – 5% DV Jan-22 to 2024	99.99	1	Epirubicin Ebewe
134	METHOTREXATE (↑ price and addition of PSS) Tab 2.5 mg – 5% DV Jan-22 to 2024	9.98	90	Trexate
	Tab 10 mg – 5% DV Jan-22 to 2024	33.71	90	Trexate
149	MEGESTROL ACETATE – Restricted: For continuation only (addition of restriction) Tab 160 mg.....	63.53	30	Apo-Megestrol
150	LETROZOLE (↑ price and addition of PSS) Tab 2.5 mg – 5% DV Jan-22 to 2024	5.84	30	Letrole
183	RITUXIMAB (RIXIMYO) (amended restriction criteria – new criteria shown only) → Inj 10 mg per ml, 10 ml vial	275.33	2	Riximyo
	→ Inj 10 mg per ml, 50 ml vial	688.20	1	Riximyo

Restricted

Initiation – B-cell acute lymphoblastic leukaemia/lymphoma*

Limited to 2 years treatment

All of the following:

- 1 Patient has newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma*;** and
- 2 Treatment must be in combination with an intensive chemotherapy protocol with curative intent;** and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² per dose for a maximum of 18 doses.**

Notes: Indications marked with * are unapproved indications.

RESPIRATORY SYSTEM AND ALLERGIES

209	CETIRIZINE HYDROCHLORIDE (↓ price and addition of PSS) Oral liq 1 mg per ml – 5% DV Jan-22 to 2024	2.84	200 ml	Histaclear
209	SALBUTAMOL WITH IPRATROPIUM BROMIDE (↑ price and addition of PSS) Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – 5% DV Jan-22 to 2024	11.04	20	Duolin
211	PIRFENIDONE (presentation change) → Tab 267 mg.....	1215.00	90	Esbriet
	Note – Esbriet cap 267 mg to be delisted 1 January 2022.			
212	SALBUTAMOL (↑ price and addition of PSS) Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 5% DV Jan-22 to 2024	8.96	20	Asthalin
	Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 5% DV Jan-22 to 2024	9.43	20	Asthalin

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2021 (continued)

SENSORY ORGANS

222	BRIMONIDINE TARTRATE (↓ price and addition of PSS) Eye drops 0.2% – 5% DV Jan-22 to 2024	4.29	5 ml	Arrow-Brimonidine
223	SODIUM HYALURONATE [HYALURONIC ACID] (↓ price, new pharmacode listing and addition of PSS) Eye drops 1 mg per ml – 5% DV Jan-22 to 2024	13.85	10 ml	Hylo-Fresh

Note – New listing is for Pharmacode 2608162. Pharmacode 2396238 to be delisted 1 January 2022.

SPECIAL FOODS

241	LOW-GI ORAL FEED 1 KCAL/ML → Liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per 100 ml, can	2.10	237 ml	Sustagen Diabetic (Vanilla)
Note – Sustagen Diabetic (Vanilla) delist is delayed from 1 October 2021 to 1 February 2022.				
243	ENTERAL FEED 2 KCAL/ML → Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle	11.00	1,000 ml	Ensure Two Cal HN RTH
Note – Two Cal HN RTH is to be delisted from 1 February 2022.				

VACCINES

252	MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE (amended restriction criteria) → Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial – 0% DV Oct-20 to 2024	0.00	1	Menactra
Restricted Initiation Either:				
1. Any of the following:				
1.1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre- or post-solid organ transplant; or				
1.2 One dose for close contacts of meningococcal cases of any group ; or				
1.3 One dose for person who has previously had meningococcal disease of any group ; or				
1.4 A maximum of two doses for bone marrow transplant patients; or				
1.5 A maximum of two doses for patients person following pre- and post-immunosuppression*				
2. Both:				
2.1 Person is aged between 13 and 25 years, inclusive; and				
2.2 Either:				
2.2.1 One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; or				
2.2.2 One dose for individuals who are currently living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, from 1 December 2019 to 30 November 2021.				
Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.				
*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.				

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2021 (continued)

253	MENINGOCOCCAL B MULTICOMPONENT VACCINE (amended restriction criteria) → Inj 175 mcg per 0.5 ml prefilled syringe	0.00	1	Bexsero
Restricted				
Initiation – Infants under one year of age				
Any of the following:				
1. up to three doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or				
2. up to three doses for close contacts of meningococcal cases of any group; or				
3. up to three doses for child who or has previously had meningococcal disease of any group; or				
4. up to three doses for bone marrow transplant patients; or				
5. up to three doses for person pre- and post-immunosuppression*				
Initiation – Person is one year of age or over				
Any of the following:				
1. up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or				
2. up to two doses for close contacts of meningococcal cases of any group; or				
3. up to two doses for person who has previously had meningococcal disease of any group; or				
4. up to two doses for bone marrow transplant patients; or				
5. up to two doses for person pre- and post-immunosuppression*				
*Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.				
253	MENINGOCOCCAL C CONJUGATE VACCINE (amended restriction criteria) → Inj 10 mcg in 0.5 ml syringe	0.00	1	Neisvac-C
Restricted				
Initiation – Children under 9 months of age				
Any of the following:				
1 Up to three doses for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or				
2 Two doses for close contacts of meningococcal cases of any group ; or				
3 Two doses for child who has previously had meningococcal disease of any group ; or				
4 A maximum of two doses for bone marrow transplant patients; or				
5 A maximum of two doses for patients child pre- and post-immunosuppression*				
Note: children under nine months of age require two doses 8 weeks apart. Refer to the Immunisation Handbook for booster schedules with meningococcal ACWY vaccine.				
*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.				

Index

Pharmaceuticals and brands

A

Aciclovir	11
Aciclovir-Baxter	11
Apo-Azithromycin	10
Apo-Diclo SR	11
Apo-Megestrol	13
Apo-Perindopril	8
Apo-Pindolol	9
Apo-Prazosin	8
Arrow-Brimonidine	14
Asthalin	13
Atenolol	8
Atropine sulphate	8
Aurorix	12
Azilect	12
Azithromycin	10

B

Beta Cream	9
Betamethasone valerate	9
Beta Ointment	9
Beta Scalp	9
Bexsero	15
Biodone	12
Biodone Extra Forte	12
Biodone Forte	12
Brimonidine tartrate	14
Brufen SR	11

C

Catapres	9
Cefepime	10
Cefepime Kabi	10
Cetirizine hydrochloride	13
Cilicaine VK	10
Clonidine hydrochloride	9
Co-trimoxazole	10
Cyclonex	12
Cyclophosphamide	12
Cyproterone acetate	10

D

Daonil	8
Dexamethasone	10
Dexamfetamine sulfate	12
Dexamethasone	10
Dextrose	8
Diclofenac Sandoz	11
Diclofenac sodium	11
Dopamine hydrochloride	9
Doxorubicin Ebewe	13
Doxorubicin hydrochloride	13
Duolin	13

E

Ensure Two Cal HN RTH	14
Enteral feed 2 kcal/ml	14
Epirubicin Ebewe	13
Epirubicin hydrochloride	13
Esbriet	13

F

Febuxostat	11
Febuxostat multichem	11
Felo 5 ER	9
Felo 10 ER	9
Felodipine	9
Fentanyl	12
Fentanyl Sandoz	12
Flucloxacillin	10

G

Glibenclamide	8
Glucose [Dextrose]	8
Glycoprep-C	8

H

Histaclear	13
Hyaluronic acid	14
Hydrocortisone with natamycin and neomycin	9
Hylo-Fresh	14
HypoPak Glucose	8

I

Ibuprofen	11
Isoniazid	10
Isoniazid with rifampicin	11

L

Letrole	13
Letrozole	13
Low-gi oral feed 1 kcal/ml	14

M

Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride	8
Magnesium hydroxide	8
Mebendazole	11
Megestrol acetate	13
Menactra	14
Meningococcal (A, C, Y and W-135) conjugate vaccine	14
Meningococcal B multicomponent vaccine	15
Meningococcal C conjugate vaccine	15
Methadone hydrochloride	12
Methotrexate	13
Midazolam	12
Mirtazapine	12
Moclobemide	12
Mylan (24 hr release)	9
Mylan Atenolol	8

Index

Pharmaceuticals and brands

Mylan Midazolam	12	R	
N		Rasagiline	12
Naprosyn SR 750	11	ReTrieve	9
Naprosyn SR 1000	11	Rifinah	11
Naproxen	11	Rituximab (riximyo)	13
Neisvac-C	15	Riximyo	13
Nevirapine	11	S	
Nevirapine Alphapharm	11	Salbutamol	13
Nifedipine	9	Salbutamol with ipratropium bromide	13
Noflam 250	11	Selegiline hydrochloride	12
Noflam 500	11	Sildenafil	9
Norflex	11	Siterone	10
Noumed	12	Sodium citrate	8
O		Sodium hyaluronate [Hyaluronic acid]	14
Omnitrope	10	Somatropin	10
Orphenadrine citrate	11	Sustagen Diabetic (Vanilla)	14
Oxytocin with ergometrine maleate	9	Syntometrine	9
P		T	
Pacimol	12	TMP	10
Pamidronate disodium	11	Tobramycin	10
Pamisol	11	Tobramycin Mylan	10
Paracetamol	12	Tretinoin	9
Paraffin	9	Trexate	13
Penicillin V	10	Trimethoprim	10
Perindopril	8	Trimethoprim with sulphamethoxazole [Co-trimoxazole]	10
Pethidine hydrochloride	12	Trisul	10
Phenoxymethylpenicillin [Penicillin V]	10	V	
Pimafucort	9	Vaclovir	11
Pindolol	9	Valaciclovir	11
Pioglitazone	8	Varenicline	12
Pirfenidone	13	Varenicline Pfizer	12
Prazosin	8	Vedafil	9
Q		Vermox	11
QV Bath Oil	9	Vexazone	8

New Zealand
Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1172-3694 (Print)

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand